Overview

Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to compare the efficacy and safety of 5% tavilermide ophthalmic solution to placebo for the treatment of the signs and symptoms of dry eye disease.
Phase:
Phase 3
Details
Lead Sponsor:
Mimetogen Pharmaceuticals USA, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions